Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients

• Main Authors: P Dalal, G Shah, D Chhabra, et al
• Format: Article
• Language: English
• Published: Dove Medical Press 2010-08-01
• Series: International Journal of Nephrology and Renovascular Disease
• Online Access: http://www.dovepress.com/role-of-tacrolimus-combination-therapy-with-mycophenolate-mofetil-in-t-a4966

P Dalal1, G Shah1, D Chhabra2, Lorenzo Gallon21Department of Medicine, Mount Sinai Hospital, Chicago; 2Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USAIntroduction: Several new medications are now available for immunosuppression in the kidney transplant field. Tacrolimus and mycophenolate mofetil were first introduced for ­immunosuppression in renal transplantation in the mid 1990s. Since then, the combination of tacrolimus and mycophenolate mofetil has been evaluated in numerous clinical trials. The outcomes of these trials have varied due to differences in induction and/or maintenance therapy, drug dosing and monitoring protocols, and study design. The aim of this review is to analyze the literature critically and to provide an overview of tacrolimus and mycophenolate mofetil combination therapy in renal transplantation.Keywords: mycophenolate mofetil, tacrolimus, kidney transplantation, immunosuppression